Xenon shares get Buy nod from H.C. Wainwright, price target unchanged
XENE Stock | USD 38.52 1.10 2.78% |
About 61% of Xenon Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Xenon Pharmaceuticals suggests that many traders are alarmed. The current market sentiment, together with Xenon Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Xenon Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
Xenon |
Xenon shares get Buy nod from H.C. Wainwright, price target unchanged
Read at investing.com
Xenon Pharmaceuticals Fundamental Analysis
We analyze Xenon Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Xenon Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Xenon Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Insiders
Shares Owned By Insiders Comparative Analysis
Xenon Pharmaceuticals is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Xenon Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Xenon Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Xenon Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Xenon Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Xenon Pharmaceuticals Related Equities
REPL | Replimune | 16.86 | ||||
VTYX | Ventyx Biosciences | 6.88 | ||||
ANAB | AnaptysBio | 6.50 | ||||
VRDN | Viridian Therapeutics | 6.27 | ||||
MGTX | MeiraGTx Holdings | 5.56 | ||||
IDYA | Ideaya Biosciences | 4.37 | ||||
CRNX | Crinetics Pharmaceuticals | 3.78 | ||||
PCVX | Vaxcyte | 3.36 | ||||
KROS | Keros Therapeutics | 3.23 | ||||
UTHR | United Therapeutics | 2.52 | ||||
ASND | Ascendis Pharma | 2.29 | ||||
MRUS | Merus BV | 0.74 | ||||
CYTK | Cytokinetics | 0.17 | ||||
ACLX | Arcellx | 0.14 | ||||
NUVL | Nuvalent | 0.20 | ||||
INBX | Inhibrx | 0.37 | ||||
LYEL | Lyell Immunopharma | 1.72 | ||||
EWTX | Edgewise Therapeutics | 1.72 | ||||
KRON | Kronos Bio | 1.98 | ||||
DYN | Dyne Therapeutics | 4.33 |
Complementary Tools for Xenon Stock analysis
When running Xenon Pharmaceuticals' price analysis, check to measure Xenon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xenon Pharmaceuticals is operating at the current time. Most of Xenon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xenon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xenon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xenon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |